435 related articles for article (PubMed ID: 7707125)
1. Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991.
Bennett CL; Armitage JL; Armitage GO; Vose JM; Bierman PJ; Armitage JO; Anderson JR
J Clin Oncol; 1995 Apr; 13(4):969-73. PubMed ID: 7707125
[TBL] [Abstract][Full Text] [Related]
2. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.
Smith TJ; Hillner BE; Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Link H; Zander A; Yanovich S; Kitchin R; Erder MH
J Clin Oncol; 1997 Jan; 15(1):5-10. PubMed ID: 8996118
[TBL] [Abstract][Full Text] [Related]
3. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease. a prospective randomised trial.
van Agthoven M; Vellenga E; Fibbe WE; Kingma T; Uyl-de Groot CA
Eur J Cancer; 2001 Sep; 37(14):1781-9. PubMed ID: 11549432
[TBL] [Abstract][Full Text] [Related]
4. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[TBL] [Abstract][Full Text] [Related]
6. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Majolino I; Pearce R; Taghipour G; Goldstone AH
J Clin Oncol; 1997 Feb; 15(2):509-17. PubMed ID: 9053472
[TBL] [Abstract][Full Text] [Related]
7. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.
Peniket AJ; Ruiz de Elvira MC; Taghipour G; Cordonnier C; Gluckman E; de Witte T; Santini G; Blaise D; Greinix H; Ferrant A; Cornelissen J; Schmitz N; Goldstone AH;
Bone Marrow Transplant; 2003 Apr; 31(8):667-78. PubMed ID: 12692607
[TBL] [Abstract][Full Text] [Related]
8. Cost comparative study of autologous peripheral blood progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin's lymphoma patients.
Woronoff-Lemsi MC; Arveux P; Limat S; Deconinck E; Morel P; Cahn JY
Bone Marrow Transplant; 1997 Dec; 20(11):975-82. PubMed ID: 9422478
[TBL] [Abstract][Full Text] [Related]
9. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
Horning SJ; Negrin RS; Chao JC; Long GD; Hoppe RT; Blume KG
J Clin Oncol; 1994 Dec; 12(12):2552-8. PubMed ID: 7989928
[TBL] [Abstract][Full Text] [Related]
10. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT
J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321
[TBL] [Abstract][Full Text] [Related]
11. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
12. Indications and relative indications for stem cell transplantation in non-Hodgkin's lymphoma.
Stewart FM
Leukemia; 1993 Jul; 7(7):1091-4. PubMed ID: 8100601
[TBL] [Abstract][Full Text] [Related]
13. Autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma.
Bolwell BJ
Semin Oncol; 1994 Aug; 21(4 Suppl 7):86-95. PubMed ID: 7916488
[TBL] [Abstract][Full Text] [Related]
14. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma.
Vose JM; Anderson JR; Kessinger A; Bierman PJ; Coccia P; Reed EC; Gordon B; Armitage JO
J Clin Oncol; 1993 Oct; 11(10):1846-51. PubMed ID: 8105034
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
[TBL] [Abstract][Full Text] [Related]
16. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
17. Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients.
Kahn ST; Flowers CR; Lechowicz MJ; Hollenbach K; Johnstone PA
Cancer J; 2005; 11(5):425-31. PubMed ID: 16259874
[TBL] [Abstract][Full Text] [Related]
18. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
Wheeler C; Eickhoff C; Elias A; Ibrahim J; Ayash L; McCauley M; Mauch P; Schwartz G; Eder JP; Mazanet R; Ferrara J; Rimm IJ; Guinan E; Bierer B; Gilliland G; Churchill WH; Ault K; Parsons S; Antman K; Schnipper L; Tepler I; Gaynes L; Frei E; Kadin M; Antin J
Biol Blood Marrow Transplant; 1997 Jun; 3(2):98-106. PubMed ID: 9267670
[TBL] [Abstract][Full Text] [Related]
19. Costs of care associated with high-dose therapy and autologous transplantation for non-Hodgkin's lymphoma: results from the University of Nebraska Medical Center 1989 to 1995.
Freeman M; Vose J; Bennett C; Anderson J; Kessinger A; Turner K; Pierson J; Bishop M; Bierman P; Armitage J
Bone Marrow Transplant; 1999 Sep; 24(6):679-84. PubMed ID: 10490736
[TBL] [Abstract][Full Text] [Related]
20. High-dose therapy and autologous transplantation for lymphoma: The Peter MacCallum Cancer Institute experience.
Dowling AJ; Prince HM; Wirth A; Wolf M; Januszewicz EH; Juneja S; Seymour JF; Gates P; Smith JG
Intern Med J; 2001 Jul; 31(5):279-89. PubMed ID: 11512599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
